Market Exclusive

Abbott Laboratories (NYSE:ABT) price target raised to $90.00 by Bank of America

Analyst Ratings For Abbott Laboratories (NYSE:ABT)

Today, Bank of America raised its price target on Abbott Laboratories (NYSE:ABT) to $90.00 per share.

There are 15 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $81.2563 per share, a potential 0.96% downside.

Some recent analyst ratings include

About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 82.01 up +0.060 0.073% with shares trading hands.

Exit mobile version